Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
What the film says
For many leukemias, a bone marrow transplant is the only cure: the donor's immune cells finish the leukemia. The same cells can also attack the patient, called graft-versus-host disease, and with a half-matched donor the risk climbs.
The idea: keep the cells that kill leukemia, and leave behind those that start the war.
Most T cells are the alpha-beta kind, which cause graft-versus-host disease. A small minority, gamma-delta T cells, recognize cancer cells directly, without the matching that triggers attacks on healthy tissue. From the donor's blood, those cells are pulled out, multiplied, and infused after transplant.
At Kansas and Ohio State, with Joseph McGuirk, the trial asks whether that is safe, and whether relapse and graft-versus-host disease drop. Public record; not medical advice.
Sources behind this film
Transplant as the only cure for many leukemias; donor cells finish the leukemia; GVHD risk climbs with a half-matched donor; Alpha-beta T cells drive GVHD; gamma-delta T cells kill malignant cells without antigen recognition; Donor blood, expanded and activated, alpha-beta depleted, infused after transplant at 1, 3, or 10 million cells/kg; Kansas and Ohio State; Joseph McGuirk; safety, GVHD rate
The drug
The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Many patients with hematological malignancies require a bone marrow transplant for curative treatment. A matched sibling donor is optimal but may not be available. Therefore, a partially matched family member (haploidentical) may be a viable alternative. The incidence of graft vs. host disease, however, can become more of a significant, even fatal, factor with partial matches. T-cells have been shown to be the key player in the post-transplant immune phenomena.
The majority of T-cells are composed of alpha beta T-cells with a small minority of gamma delta T-cells, which are known to have the unique ability to kill malignant cells without antigen recognition. This study proposes to extract, concentrate, and activate gamma delta T-cells from the peripheral blood to provide innate anti-tumor effect with minimal risk of GVHD. Safety and impact and/or the rate of GVHD will be evaluated.
The study
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.